Eupraxia Pharmaceuticals Announces Key Presentations for Investors
Eupraxia Pharmaceuticals Confirmed to Present at Upcoming Conferences
Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) (TSX: EPRX), an innovative clinical-stage biotechnology company, has exciting news as their management and scientific teams are preparing to engage with the medical and investment communities at several conferences this spring. These gatherings are pivotal opportunities for Eupraxia to share the latest advancements in their proprietary DiffuSphere™ technology, which is engineered to enhance drug delivery for critical unmet medical needs.
Highlighting Research at the OARSI World Congress
One major event is the Osteoarthritis Research Society International World Congress scheduled for late April. Dr. Phil Conaghan, from the Company’s OA Clinical Advisory Board, will showcase substantial findings regarding EP-104IAR, an extended-release formulation of fluticasone propionate designed to relieve pain associated with knee osteoarthritis. This presentation will occur during a dedicated poster session on April 25-26.
Key Poster Information
The content of Dr. Conaghan's poster emphasizes the sustained pain relief experienced by subjects with moderate baseline pain and body mass index (BMI) under 30, stemming from a robust Phase 2 study, SPRINGBOARD. This research represents a significant stride toward optimizing pain management strategies.
Digestive Disease Week Annual Meeting Insights
Following the OARSI Congress, Eupraxia will participate in the Digestive Disease Week (DDW) Annual Meeting from May 3-6. This is an important venue for discussing the Phase 1b study outcomes of EP-104GI, which targets eosinophilic esophagitis (EoE), a condition marked by inflammation in the esophagus.
Poster Sessions at DDW
Dr. Evan Dellon will present critical data on the dose-escalation studies, while Dr. Amanda Malone will discuss the epidemiology surrounding esophageal strictures. By presenting this data, Eupraxia aims to shed light on innovative treatment options and address the pressing challenges faced by patients suffering from EoE.
Engagement Opportunities at the Bloom Burton & Co. Conference
On May 5, Eupraxia's CEO, Dr. James Helliwell, will take the stage at the Bloom Burton & Co. Healthcare Investor Conference in Toronto, delivering insights on the Company’s strategic direction and performance. This conference represents a prime opportunity for investors to glean insights directly from the leadership about Eupraxia's innovative approaches and future prospects.
Upcoming Presentation at the ESDE Congress
Finally, Eupraxia will be involved in the European Society for Diseases of the Esophagus Annual Congress happening from May 11-13. On May 12, Dr. Arjan Bredenoord will present research findings relevant to esophageal treatments, reinforcing Eupraxia's commitment to advancing therapeutic innovations.
After these conferences, all poster presentations and related materials will be accessible on Eupraxia's website, ensuring that stakeholders can engage with the latest research findings and advancements in drug development.
About Eupraxia Pharmaceuticals Inc.
Eupraxia is dedicated to revolutionizing drug delivery through its DiffuSphere™ technology, which promises enhanced therapeutic efficacy by allowing precise, localized drug administration. This pioneering approach is crucial for addressing high unmet medical needs across several therapeutic areas, including osteoarthritis and eosinophilic esophagitis. With ongoing trials like the Phase 1b/2a study of EP-104GI and the recent successful completion of the Phase 2b SPRINGBOARD trial for knee osteoarthritis, Eupraxia is well-positioned to make significant impacts on patient care.
For any inquiries regarding the Company, please contact:
Danielle Egan, Eupraxia Pharmaceuticals Inc.
Contact Number: 778.401.3302
Email: degan@eupraxiapharma.com
or
Kevin Gardner, on behalf of:
Eupraxia Pharmaceuticals Inc.
Contact Number: 617.283.2856
Email: kgardner@lifesciadvisors.com
Frequently Asked Questions
What is Eupraxia Pharmaceuticals' focus?
Eupraxia Pharmaceuticals is focused on developing locally delivered, extended-release products that address areas with significant medical needs.
What technology does Eupraxia use?
The Company utilizes its proprietary DiffuSphere™ technology to optimize drug delivery, enhancing therapeutic outcomes and minimizing adverse effects.
When are the upcoming conferences Eupraxia will present at?
Eupraxia will present at several conferences, including the OARSI World Congress, DDW Annual Meeting, Bloom Burton & Co. Conference, and ESDE Congress, throughout April and May.
What is EP-104GI used for?
EP-104GI is being studied as a treatment for eosinophilic esophagitis (EoE), providing an innovative approach to this condition.
How can I learn more about Eupraxia's research?
Details regarding Eupraxia’s ongoing studies and findings can be found on the Company's official website.
About The Author
Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
